These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1026529)

  • 1. The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.
    Ward JW; Kinghorn GR
    J Int Med Res; 1976; 4(1 Suppl):49-53. PubMed ID: 1026529
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-arrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia.
    Hulting J; Rosenhamer G
    J Int Med Res; 1976; 4(1 Suppl):90-5. PubMed ID: 1026537
    [No Abstract]   [Full Text] [Related]  

  • 3. Some aspects of the clinical pharmacology of intravenous disopyramide after myocardial infarction.
    Hillis WS; Tweddel A; Lorimer AR; Lawrie TD
    J Int Med Res; 1976; 4(1 Suppl):74-7. PubMed ID: 1026533
    [No Abstract]   [Full Text] [Related]  

  • 4. Disopyramide kinetics in patients with acute myocardial infarction.
    Ilett KF; Madsen BW; Woods JD
    Clin Pharmacol Ther; 1979 Jul; 26(1):1-7. PubMed ID: 445953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous and oral disopyramide after myocardial infarction.
    Nicholls DP; Haybyrne T; Barnes PC
    Lancet; 1980 Nov; 2(8201):936-8. PubMed ID: 6107587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral disopyramide in the prevention of ventricular arrhythmias following myocardial infarction in patients managed on the coronary care unit and open ward.
    Kidner PH; Carmichael DJ
    East Afr Med J; 1978 Aug; 55(8):403-6. PubMed ID: 699858
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics of disopyramide administered by intramuscular, intravenous and oral routes to normal volunteers [proceedings].
    Ashford JJ; Carmichael D; Kidner PH
    Br J Pharmacol; 1979 Jul; 66(3):442P-443P. PubMed ID: 526732
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacokinetic and metabolic study of disopyramide in oral and intravenous administration].
    De Graeve J; Kremers P; Gielen JE
    Therapie; 1977; 32(2):195-204. PubMed ID: 898127
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma disopyramide concentrations following a 300-mg oral loading dose in acute myocardial infarction.
    Weissberg PL; Matenga J; Hayler AM; Holt DW
    Ther Drug Monit; 1982; 4(3):277-80. PubMed ID: 7135457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachyarrhythmia.
    Rangno RE; Warnica W; Ogilvie RI; Kreeft J; Bridger E
    J Int Med Res; 1976; 4(1 Suppl):54-8. PubMed ID: 1026530
    [No Abstract]   [Full Text] [Related]  

  • 11. Disopyramide plasma concentrations following single and multiple doses of the immediate- and controlled-release capsules.
    Karim A; Schubert EN; Burns TS; Palmer M; Zinny MA
    Angiology; 1983 Jun; 34(6):375-92. PubMed ID: 6346960
    [No Abstract]   [Full Text] [Related]  

  • 12. The pharmacokinetics of disopyramide in patients with acute myocardial infarction.
    Jounela AJ; Pentikäinen PJ; Oksanen K
    Int J Clin Pharmacol Ther Toxicol; 1982 Jun; 20(6):276-82. PubMed ID: 7107076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma binding of disopyramide.
    David BM; Madsen BW; Ilett KF
    Br J Clin Pharmacol; 1980 Jun; 9(6):614-8. PubMed ID: 7387819
    [No Abstract]   [Full Text] [Related]  

  • 14. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
    Aitio ML; Allonen H; Kanto J; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.
    David BM; Ilett KF; Whitford EG; Stenhouse NS
    Br J Clin Pharmacol; 1983 Apr; 15(4):435-41. PubMed ID: 6849779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog.
    Cook CS; Karim A; Sollman P
    Drug Metab Dispos; 1982; 10(2):116-21. PubMed ID: 6124395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disopyramide in acute myocardial infarction: problems with changing pharmacokinetics.
    Elliott HL; Thomson AH; Bryson SM
    Eur J Clin Pharmacol; 1986; 30(3):345-7. PubMed ID: 3732373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous disopyramide in myocardial infarction: a haemodynamic study.
    Marrott PK; Nairn PL; Hill PD; Turner G; Sharman J
    N Z Med J; 1983 Jan; 96(723):4-7. PubMed ID: 6571755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of oral disopyramide on mortality and extension of infarction in cases of acute myocardial infarction admitted to open wards.
    Sharma BD; Chug S; Mathur KP
    J Assoc Physicians India; 1983 Mar; 31(3):149-51. PubMed ID: 6352667
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacodynamics and pharmacokinetics of disopyramide phosphate].
    Ol'binskaia LI; Tiukavkina NA; Kuz'mina MM; Beloborodov VL; Klimov AV
    Farmakol Toksikol; 1985; 48(4):73-8. PubMed ID: 3930285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.